ATE487471T1 - Therapeutische formulierung zur verabreichung von tolterodin mit kontrollierter freisetzung - Google Patents

Therapeutische formulierung zur verabreichung von tolterodin mit kontrollierter freisetzung

Info

Publication number
ATE487471T1
ATE487471T1 AT99946521T AT99946521T ATE487471T1 AT E487471 T1 ATE487471 T1 AT E487471T1 AT 99946521 T AT99946521 T AT 99946521T AT 99946521 T AT99946521 T AT 99946521T AT E487471 T1 ATE487471 T1 AT E487471T1
Authority
AT
Austria
Prior art keywords
administration
controlled release
therapeutic formulation
release tolterodine
tolterodine
Prior art date
Application number
AT99946521T
Other languages
English (en)
Inventor
Lisbeth Nilvebrant
Bengt Hallen
Birgitta Olsson
Jan Stroembom
Bo Kreilgard
Jacobsen Lene Orup
Ulla Hoeck
Helle Kristensen
Torkel Gren
Anders Ringberg
Martin Wikberg
Original Assignee
Pfizer Health Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26663376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE487471(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE9802864A external-priority patent/SE9802864D0/xx
Priority claimed from SE9803871A external-priority patent/SE9803871D0/xx
Application filed by Pfizer Health Ab filed Critical Pfizer Health Ab
Application granted granted Critical
Publication of ATE487471T1 publication Critical patent/ATE487471T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AT99946521T 1998-08-27 1999-08-26 Therapeutische formulierung zur verabreichung von tolterodin mit kontrollierter freisetzung ATE487471T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9802864A SE9802864D0 (sv) 1998-08-27 1998-08-27 Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder
SE9803871A SE9803871D0 (sv) 1998-11-11 1998-11-11 Therapeutic method and formulation
PCT/SE1999/001463 WO2000012069A1 (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release

Publications (1)

Publication Number Publication Date
ATE487471T1 true ATE487471T1 (de) 2010-11-15

Family

ID=26663376

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99946521T ATE487471T1 (de) 1998-08-27 1999-08-26 Therapeutische formulierung zur verabreichung von tolterodin mit kontrollierter freisetzung

Country Status (30)

Country Link
US (1) US6770295B1 (de)
EP (2) EP2153825A1 (de)
CN (1) CN1239152C (de)
AP (1) AP1529A (de)
AR (1) AR029311A1 (de)
AT (1) ATE487471T1 (de)
AU (1) AU745190B2 (de)
BG (1) BG65168B1 (de)
CA (1) CA2311755C (de)
CY (1) CY1111088T1 (de)
CZ (1) CZ302630B6 (de)
DE (1) DE69942928D1 (de)
DK (1) DK1039882T3 (de)
EA (1) EA002720B1 (de)
GE (1) GEP20043354B (de)
HU (1) HUP0100437A3 (de)
ID (1) ID25824A (de)
IL (1) IL136294A (de)
IS (1) IS2976B (de)
ME (1) ME00850B (de)
MY (1) MY127946A (de)
NO (1) NO329830B1 (de)
NZ (1) NZ504618A (de)
OA (1) OA11636A (de)
PT (1) PT1039882E (de)
SI (1) SI1039882T1 (de)
SK (1) SK287111B6 (de)
TR (1) TR200001998T1 (de)
UA (1) UA72882C2 (de)
WO (1) WO2000012069A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (de) 1998-05-12 1999-11-17 Schwarz Pharma Ag 3,3-Diphenylpropylaminderivate
DE19922662C1 (de) 1999-05-18 2000-12-28 Sanol Arznei Schwarz Gmbh Transdermales therapeutisches System (TTS) Tolterodin enthaltend
DE19932651A1 (de) * 1999-07-13 2001-01-18 Hexal Ag Transdermales therapeutisches System zur Anwendung von Tolterodin
DE60021749T2 (de) * 1999-11-11 2006-04-20 Pfizer Health Ab Pharmazeutische formulierung enthaltend tolterodin sowie ihre verwendung
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US20030185882A1 (en) 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
WO2003039524A1 (en) * 2001-11-09 2003-05-15 Pharmacia Ab Anti-muscarinic agent and estrogen-agonist for treating unstable or overactive bladder
US6773421B2 (en) 2001-12-14 2004-08-10 Kimberly-Clark Worlwide, Inc. Combination for managing the involuntary loss of bladder control
EP1424079A1 (de) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Kombination eines beta-3-Rezeptoragonisten und eines Serotonin und/oder Norepinephrin-Wiederaufnahmeinhibitors
DE60332387D1 (de) * 2002-12-13 2010-06-10 Warner Lambert Co Alpha-2-delta-ligand zur behandlung vonsymptomen der unteren harnwege
ATE432070T1 (de) * 2003-01-22 2009-06-15 Pfizer Health Ab Herabgesetzte dosis von tolterodin zur behandlung von harnwegserkrankungen
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
WO2004105735A1 (en) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Controlled release pharmaceutical compositions of tolterodine and processes for their preparation
DK2210605T3 (en) 2003-11-04 2017-05-22 Tcd Royalty Sub Llc Daily single dose doses of trospium.
WO2005046663A1 (en) 2003-11-04 2005-05-26 Shire Laboratories, Inc. Compositions of quaternary ammonium containing bioavailability enhancers
WO2005105036A1 (en) * 2004-04-28 2005-11-10 Natco Pharma Limited Controlled release mucoadhesive matrix formulation containing tolterodine and a process for its preparation
EP1629834A1 (de) † 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Pharmazeutische Zusammensetzung von Tolterodin mit verzögerter Freisetzung
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
RU2301086C2 (ru) * 2004-12-27 2007-06-20 Государственное образовательное учреждение высшего профессионального образования Алтайский государственный медицинский университет Минздрава России (ГОУ ВПО АГМУ МЗ РФ) Способ лечения гиперактивного мочевого пузыря
JP5666087B2 (ja) 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Ｃｎｓ関連疾患の治療のための方法及び組成物
CN1330297C (zh) * 2005-07-04 2007-08-08 宛六一 酒石酸托特罗定软胶囊及其制备方法
KR20070012205A (ko) * 2005-07-22 2007-01-25 주식회사종근당 경시 안정성을 갖는 톨테로딘을 함유하는 제어방출형 펠렛
CA2882048C (en) 2006-02-03 2020-03-24 Opko Renal, Llc Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
WO2007122015A1 (en) * 2006-04-21 2007-11-01 Synthon B.V. Tolterodine beads
HUE037309T2 (hu) 2006-06-21 2018-08-28 Opko Ireland Global Holdings Ltd Terápia D-vitamin telítési szer alkalmazásával és D-vitamin hormon helyettesítõ szer
ES2401205T3 (es) 2007-04-25 2013-04-17 Cytochroma Inc. Composiciones de orales de liberación controlada que comprende un compuesto de vitamina D y un soporte céreo
CA2683514C (en) 2007-04-25 2019-07-09 Proventiv Therapeutics, Llc Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
WO2009047644A2 (en) 2007-04-25 2009-04-16 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
US20090017111A1 (en) * 2007-07-03 2009-01-15 Van Den Heuvel Dennie J M Tolterodine bead
US8486452B2 (en) 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
US8871275B2 (en) 2007-08-08 2014-10-28 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
US20090192228A1 (en) * 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
KR101685031B1 (ko) 2008-04-02 2016-12-09 사이토크로마 인코포레이티드 비타민 ｄ 결핍 및 관련 장애에 유용한 방법, 조성물, 용도 및 키트
TWI541246B (zh) 2008-12-08 2016-07-11 歐陸斯迪公司 二氫羥戊甲嗎啡
KR101004205B1 (ko) * 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
RU2396920C1 (ru) * 2008-12-29 2010-08-20 Николай Владимирович Карюкин Способ лечения гиперактивного мочевого пузыря
WO2011095388A1 (en) 2010-02-04 2011-08-11 Synthon Bv Tolterodine bead
KR101746204B1 (ko) * 2010-02-18 2017-06-13 에스케이케미칼주식회사 피부 투과가 개선된 톨테로딘의 경피 투여용 조성물
CN103037902A (zh) 2010-03-29 2013-04-10 赛特克罗公司 用于降低甲状旁腺水平的方法和组合物
AU2011245499B2 (en) 2010-04-30 2014-09-25 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
DE102010024105A1 (de) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
US20130195957A1 (en) * 2010-08-03 2013-08-01 Hisamitsu Pharmaceutical Co., Inc. Patch and method for enhancing adhesion force of the same
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
EP4596045A3 (de) 2016-03-28 2025-10-15 EirGen Pharma Ltd. Verfahren zur behandlung von vitamin d
EP3808336A1 (de) * 2019-10-16 2021-04-21 ADD Advanced Drug Delivery Technologies, Ltd. Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US5382600A (en) * 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
SE8800207D0 (sv) 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
JP3786684B2 (ja) * 1992-05-13 2006-06-14 アルザ・コーポレーション オキシブチニンの経皮投与
SE9203318D0 (sv) 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
WO1996012477A1 (en) * 1994-10-21 1996-05-02 Leiras Oy Controlled release oral delivery system containing oxybutynin
US5677346A (en) * 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
CA2259012C (en) * 1996-07-19 2008-05-13 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
KR20010029519A (ko) * 1996-09-19 2001-04-06 이곤 이 버그 요실금 치료 방법

Also Published As

Publication number Publication date
AP1529A (en) 2006-01-03
AP2000001823A0 (en) 2000-06-30
AR029311A1 (es) 2003-06-25
ME00850B (me) 2008-08-07
EA002720B1 (ru) 2002-08-29
HK1034664A1 (en) 2001-11-02
CA2311755C (en) 2010-03-23
US6770295B1 (en) 2004-08-03
ID25824A (id) 2000-11-09
TR200001998T1 (tr) 2001-01-22
HUP0100437A2 (hu) 2002-05-29
IS5537A (is) 2000-06-15
EA200000468A1 (ru) 2000-12-25
DK1039882T3 (da) 2011-01-24
PT1039882E (pt) 2011-01-03
BG104476A (en) 2000-12-29
CN1287484A (zh) 2001-03-14
SK7492000A3 (en) 2001-02-12
NO20002977D0 (no) 2000-06-09
DE69942928D1 (de) 2010-12-23
UA72882C2 (uk) 2005-05-16
CN1239152C (zh) 2006-02-01
SK287111B6 (sk) 2009-12-07
CA2311755A1 (en) 2000-03-09
OA11636A (en) 2004-09-03
CZ20001924A3 (cs) 2001-04-11
SI1039882T1 (sl) 2011-01-31
EP1039882B1 (de) 2010-11-10
NO20002977L (no) 2000-06-09
IL136294A0 (en) 2001-05-20
GEP20043354B (en) 2004-04-13
IS2976B (is) 2017-07-15
BG65168B1 (bg) 2007-05-31
EP1039882A1 (de) 2000-10-04
AU5891899A (en) 2000-03-21
IL136294A (en) 2004-02-08
NO329830B1 (no) 2011-01-03
CZ302630B6 (cs) 2011-08-10
HUP0100437A3 (en) 2002-08-28
MY127946A (en) 2007-01-31
EP2153825A1 (de) 2010-02-17
AU745190B2 (en) 2002-03-14
CY1111088T1 (el) 2015-06-11
NZ504618A (en) 2002-09-27
WO2000012069A1 (en) 2000-03-09

Similar Documents

Publication Publication Date Title
DE69942928D1 (de) Therapeutische formulierung zur verabreichung von tolterodin mit kontrollierter freisetzung
ATE447947T1 (de) Pharmazeutische zubereitungen zur behandlung von insulinresitenz
DE69535297D1 (de) Zubereitung multivesikulärer liposomen zur gesteuerten freisetzung von wirkstoffen
DK0797991T3 (da) Lægemiddelformulering med forhalet frigivelse
DE69935681D1 (de) Vorrichtungen zur Medikamentverabreichung
DE69634572D1 (de) Perfusionssytem zur hyperthermiebehandlung
DE60024988D1 (de) Herstellung von therapeutischem mikroschaum
DE69807634D1 (de) Medizinische einrichtung zur verabreichung von therapeutischen wirkstoffen
DE69710095D1 (de) Pharmazeutische zubereitung zur behandlung von diabetes
DE69030825D1 (de) Katheter zur gleichmässigen Verteilung von therapeutischen Flüssigkeiten
ATE401859T1 (de) Vorrichtungen zur verabreichung von arzneistoffen mit antiprogestinischen eigenschaften
DE69831421D1 (de) Zusammensetzungen zur nasalen verabreichung
DE60224111D1 (de) Bausatz zur Herstellung einer Verabreichungsform zur Abgabe einer bioaktiven Substanz
ATE240107T1 (de) Neue verbesserte formulierung zur behandlung der osteoporose
DE69530519D1 (de) Parathyroidhormon pth enthaltende therapeutische zubereitung zur inhalation
DE59910858D1 (de) Pharmazeutische zubereitung von moxifloxacin
DE69829254D1 (de) Arzneistoffzubereitung mit kontrollierter Wirkstofffreisetzungsrate
DE69827357D1 (de) Menschliches Wachstumshormon enthaltende pharmazeutische Zusammensetzung
ATE220547T1 (de) Arzneimittelformulierung mit kontrollierter wirkstofffreisetzung
DE69737067D1 (de) Vakzine zur behandlung von mycosen
DE69838785D1 (de) Pharmazeutische mittel zur behandlung von zerebralen amyloidosis
DE69716223D1 (de) Vorrichtung zur Herstellung von medizinischen Pflastern zur perkutanen Verabreichung
DE69823275T2 (de) Verfahren zur Herstellung von Vorrichtungen zur kontrollierten Freisetzung von Arzneimitteln
NO991164D0 (no) Farmas°ytisk preparat for behandling av virussykdommer
DE69821096D1 (de) Pflaster-zubereitungen zur transdermalen absorption

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1039882

Country of ref document: EP